Michael Matthews – In Memoriam

In the summer of 2001, Mike Matthews is dying. He becomes part of a small group of cancer patients whose gastrointestinal stromal tumors dramatically respond to an experimental drug, STI571. The tumors that were about to take his life begin to shrink until they are more than 80 percent gone.